{"name":"AceLink Therapeutics, Inc.","slug":"acelink-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AL01211","genericName":"AL01211","slug":"al01211","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AL01211","genericName":"AL01211","slug":"al01211","phase":"phase_2","mechanism":"AL01211 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQN0E0bVRxZHRPaEFhRHgtckptY2FxcXppSnhRSk1VRW00LVEzUVdmbS10ZmROb0h6WEg5TE1EOHFnSEd6UEhqYzJUSnVYN1ctaVRJbjZyY3pSbHotMTRXV2VUUTFJaXFQUFhWbmJDYlFYSXNmNlpoeDFRemVSejY2QVhjU1laVTNoNzF6U2pXLWY2SUEyYWR6MjR3Z0lIYm1wdDI1VmhScU9jNU8wcnBhUHBkeE5LM1hrZnR6RTVIU08zSWVFNERaX1cwN3NWWFJaX1liNlI2YS1HMTRR?oc=5","date":"2025-08-15","type":"trial","source":"BioSpace","summary":"AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients - BioSpace","headline":"AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxNdTNzWk54c2FpMG5vYTFrWGRvd1c3N1JDb0NoUHI3YldaejNiVVNMbDVpNzA0WG84QzJ1bWtLOGJqb0VTa0xMa3pjNnBJeE9qRDItYnFkQU9FN2RWeXhkMEV1SVFsbEtHaHhkWHhsRVZ5blFVY3lYS1l1X3MzYTI5SDdoM1BrSW02Rm0yMmlHZDdOLWYwN0NoVTBhNnp5U1BpR0tLVk1ac2VSZFpkUGptWVo1aG5oNVZuSGlTWmRfT1FnVExqZ3hCZHVkZUFYa2pMN2NwVzM1aWxGV0ktZVMwUEVjX1JoazBrRXplU3RIU2lXVE55UnQwem5PY1RBSnRJVG1pTkM1QXItTHNpTWlyWkM5RW1LcE5YcmI5MDF5blhOeGFDb2ZIX1NEbUFVbzhqV2ktelFVVTJ2YTVxQU5fVlA4d0F6bkVOR2VoeHh6NDdwN2l2?oc=5","date":"2025-02-07","type":"trial","source":"Business Wire","summary":"AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025 - Business Wire","headline":"AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Clas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOcXRqVXF5ZHpGMkhCZmd1UG0tU3ItSkNHS0tZbmhtbUlzeUNMOWRrbWotalM2SlZscXpQaTJGaUlQcjBTN3hpbk05bEMyYkVBOUNLUWhvQ05nbzBtWXloRXRBWUdHOU9TVFRuR1c5NnpMTlJ0REVvZHRqdV9NMFVZbG9hNjhvWnFZLVpTeTRtN2lmeGJJeWJhRHZGN1hMQQ?oc=5","date":"2024-03-06","type":"pipeline","source":"Stock Titan","summary":"Latest Updates of Viva Biotech's Portfolio Companies - Stock Titan","headline":"Latest Updates of Viva Biotech's Portfolio Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNMmVxZVRJTWVMZFhMVkZiVjdGOUdtY2tXM2ctVVZsdkZSY1dRb0NjcXBKTjFST0VFc0Q2eXl6aUk5Mm9hamNtaUJCT1U2NE9Od1hxUzR3MlVwX3d3MExfWHNDUDZnUmF0RjQxX0Z4WU1jV25GUktBSEZQOXFObUFLUzhR?oc=5","date":"2023-06-22","type":"regulatory","source":"Clinical Trials Arena","summary":"AceLink Therapeutics approved to begin Fabry disease drug trial - Clinical Trials Arena","headline":"AceLink Therapeutics approved to begin Fabry disease drug trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOdmFseV9ZVGpIRVRJdUpMYlVKS2x3NDhiaVZxNGhuaTdyd19yanRDUUl3a2RVSHZKWms0dW9JeThqeGx0THFJV1ZnMnJMMFBDSl9FSENtWmhYZ29TeUNGamt6WTF4NkI1VndfREszNnlCaTNsOGJ0ejNhNWNSOE1MLXNNT0V1WVVid1dRc0IxR2RIallHRmVBOWtlSjBtZ1FrOXRfNlh2dFlCMVpPUEp4WEdvbXFLU2V3d2hCLWMyeEMtVEg5SW1SQ2RWSnZENmxMNzhGcFZMS1EwdERHdnVfN042bmhSTzJHX1VvZWlYbzhMME5DVFVSM1ktZXQ?oc=5","date":"2022-09-19","type":"pipeline","source":"PR Newswire","summary":"Autosomal Dominant Polycystic Kidney Disease Market to Surge at a Significant CAGR of 14.5% by 2032 | DelveInsight - PR Newswire","headline":"Autosomal Dominant Polycystic Kidney Disease Market to Surge at a Significant CAGR of 14.5% by 2032 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}